Pei Xin Li, Jing Yi Han, Wei Zheng, Ran Shen, Nan Meng, Bing Nan Ren, Yi Xuan Yan, Yue Yang, Man Yu Hu, Yi Chun Guan
{"title":"非整倍体植入前基因检测与常规体外受精/胞浆内单精子注射的复发性流产患者累积活产率的比较分析：一项回顾性研究。","authors":"Pei Xin Li, Jing Yi Han, Wei Zheng, Ran Shen, Nan Meng, Bing Nan Ren, Yi Xuan Yan, Yue Yang, Man Yu Hu, Yi Chun Guan","doi":"10.1186/s13048-025-01721-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Recurrent pregnancy loss (RPL) affects 1-2% of women worldwide and poses diagnostic and therapeutic challenges due to its multifactorial causes. Preimplantation genetic testing for aneuploidy (PGT-A) aims to improve outcomes by selecting euploid embryos, but its benefits in RPL patients remain uncertain. This study compared the effectiveness of PGT-A versus conventional in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) in improving cumulative live birth rates (CLBRs) and explored the effects of maternal age and miscarriage frequency on treatment efficacy.</p><p><strong>Methods: </strong>This study included RPL patients who underwent their first oocyte retrieval and at least one single-blastocyst transfer between June 2016 and June 2022. Patients were divided into an IVF/ICSI group (n = 156) and a PGT-A group (n = 198). Primary outcomes included the CLBR, live birth rate, miscarriage rate, time to live birth, and perinatal outcomes.</p><p><strong>Results: </strong>After three single-blastocyst transfer cycles, no significant difference was observed in the conservative CLBR between the PGT-A and IVF/ICSI groups (Cycle 1: adjusted odds ratio [aOR] = 0.78, 95% confidence interval [CI]: 0.49-1.23; Cycle 2: aOR = 0.81, 95% CI: 0.51-1.29; Cycle 3: aOR = 0.96, 95% CI: 0.60-1.53; all P > 0.05). Similarly, the optimal CLBR after three transfer cycles showed no significant difference between the two groups (P > 0.05). However, the time to live birth was significantly longer in the PGT-A group than in the IVF/ICSI group (adjusted hazard ratio = 0.56, 95% CI: 0.42-0.75, P < 0.05). Other outcomes were comparable between the two groups.</p><p><strong>Conclusion: </strong>PGT-A did not significantly improve the CLBR or shorten the time to live birth in RPL patients. Further research is needed to elucidate its role and identify potential subgroups within the RPL population that may benefit from PGT-A.</p>","PeriodicalId":16610,"journal":{"name":"Journal of Ovarian Research","volume":"18 1","pages":"141"},"PeriodicalIF":4.2000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224449/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparative analysis of cumulative live birth rates in patients with recurrent pregnancy loss undergoing preimplantation genetic testing for aneuploidy versus conventional in vitro fertilisation/intracytoplasmic sperm injection: a retrospective study.\",\"authors\":\"Pei Xin Li, Jing Yi Han, Wei Zheng, Ran Shen, Nan Meng, Bing Nan Ren, Yi Xuan Yan, Yue Yang, Man Yu Hu, Yi Chun Guan\",\"doi\":\"10.1186/s13048-025-01721-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Recurrent pregnancy loss (RPL) affects 1-2% of women worldwide and poses diagnostic and therapeutic challenges due to its multifactorial causes. Preimplantation genetic testing for aneuploidy (PGT-A) aims to improve outcomes by selecting euploid embryos, but its benefits in RPL patients remain uncertain. This study compared the effectiveness of PGT-A versus conventional in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) in improving cumulative live birth rates (CLBRs) and explored the effects of maternal age and miscarriage frequency on treatment efficacy.</p><p><strong>Methods: </strong>This study included RPL patients who underwent their first oocyte retrieval and at least one single-blastocyst transfer between June 2016 and June 2022. Patients were divided into an IVF/ICSI group (n = 156) and a PGT-A group (n = 198). Primary outcomes included the CLBR, live birth rate, miscarriage rate, time to live birth, and perinatal outcomes.</p><p><strong>Results: </strong>After three single-blastocyst transfer cycles, no significant difference was observed in the conservative CLBR between the PGT-A and IVF/ICSI groups (Cycle 1: adjusted odds ratio [aOR] = 0.78, 95% confidence interval [CI]: 0.49-1.23; Cycle 2: aOR = 0.81, 95% CI: 0.51-1.29; Cycle 3: aOR = 0.96, 95% CI: 0.60-1.53; all P > 0.05). Similarly, the optimal CLBR after three transfer cycles showed no significant difference between the two groups (P > 0.05). However, the time to live birth was significantly longer in the PGT-A group than in the IVF/ICSI group (adjusted hazard ratio = 0.56, 95% CI: 0.42-0.75, P < 0.05). Other outcomes were comparable between the two groups.</p><p><strong>Conclusion: </strong>PGT-A did not significantly improve the CLBR or shorten the time to live birth in RPL patients. Further research is needed to elucidate its role and identify potential subgroups within the RPL population that may benefit from PGT-A.</p>\",\"PeriodicalId\":16610,\"journal\":{\"name\":\"Journal of Ovarian Research\",\"volume\":\"18 1\",\"pages\":\"141\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224449/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Ovarian Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13048-025-01721-3\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"REPRODUCTIVE BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ovarian Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13048-025-01721-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"REPRODUCTIVE BIOLOGY","Score":null,"Total":0}
Comparative analysis of cumulative live birth rates in patients with recurrent pregnancy loss undergoing preimplantation genetic testing for aneuploidy versus conventional in vitro fertilisation/intracytoplasmic sperm injection: a retrospective study.
Background: Recurrent pregnancy loss (RPL) affects 1-2% of women worldwide and poses diagnostic and therapeutic challenges due to its multifactorial causes. Preimplantation genetic testing for aneuploidy (PGT-A) aims to improve outcomes by selecting euploid embryos, but its benefits in RPL patients remain uncertain. This study compared the effectiveness of PGT-A versus conventional in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) in improving cumulative live birth rates (CLBRs) and explored the effects of maternal age and miscarriage frequency on treatment efficacy.
Methods: This study included RPL patients who underwent their first oocyte retrieval and at least one single-blastocyst transfer between June 2016 and June 2022. Patients were divided into an IVF/ICSI group (n = 156) and a PGT-A group (n = 198). Primary outcomes included the CLBR, live birth rate, miscarriage rate, time to live birth, and perinatal outcomes.
Results: After three single-blastocyst transfer cycles, no significant difference was observed in the conservative CLBR between the PGT-A and IVF/ICSI groups (Cycle 1: adjusted odds ratio [aOR] = 0.78, 95% confidence interval [CI]: 0.49-1.23; Cycle 2: aOR = 0.81, 95% CI: 0.51-1.29; Cycle 3: aOR = 0.96, 95% CI: 0.60-1.53; all P > 0.05). Similarly, the optimal CLBR after three transfer cycles showed no significant difference between the two groups (P > 0.05). However, the time to live birth was significantly longer in the PGT-A group than in the IVF/ICSI group (adjusted hazard ratio = 0.56, 95% CI: 0.42-0.75, P < 0.05). Other outcomes were comparable between the two groups.
Conclusion: PGT-A did not significantly improve the CLBR or shorten the time to live birth in RPL patients. Further research is needed to elucidate its role and identify potential subgroups within the RPL population that may benefit from PGT-A.
期刊介绍：
Journal of Ovarian Research is an open access, peer reviewed, online journal that aims to provide a forum for high-quality basic and clinical research on ovarian function, abnormalities, and cancer. The journal focuses on research that provides new insights into ovarian functions as well as prevention and treatment of diseases afflicting the organ.
Topical areas include, but are not restricted to:
Ovary development, hormone secretion and regulation
Follicle growth and ovulation
Infertility and Polycystic ovarian syndrome
Regulation of pituitary and other biological functions by ovarian hormones
Ovarian cancer, its prevention, diagnosis and treatment
Drug development and screening
Role of stem cells in ovary development and function.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
